KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

NCT04165096 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Boserolimab
BIOLOGICAL: MK-4830
DRUG: diphenhydramine
DRUG: acetaminophen
BIOLOGICAL: MK-0482

Sponsor

Merck Sharp & Dohme LLC